Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

Click for more information

0.00%

20.5¢ raptor resources limited

Ann: Annual General Meeting Presentation, page-19

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 19 Last

Share
Profile

Follow
Chuckybee

716 Posts.

194

28/11/19

12:43

Post #: 41683711
Share
Originally posted by Elusive Lahood ↑

I attended the AGM today. I was very impressed with the way Tony handled himself and what he is doing with the company.

Below are some rough notes i took during the Q&A. Hope they are useful for those that weren't able to attend. Standard disclaimer applies... DYOR
Q&A:

DAPRA – Programme looking at US military personnel readiness deploy (passively monitoring health) – measuring lung health specifically, wearable devices and smartphones.

Key differences to current ResApp programmes– 24/7 monitoring and passive monitoring

Addressable market: 24/7 monitoring is Resapp’s long term end game

DAPRA – using mobile phones not wearables atm…

MSF partnership / humanitarian organisations

Defocussed over last few years… haven’t reached out to developing world in the last 2 yrs

Current - Refocussed some team members on emerging markets

Sleep ap

CE mark only – can be based off aus data

FDA – there is a risk taking aus data to FDA

Still evaluating risk as to whether to rely on aus data exclusively – noting that the study in this case at least was based off the same gold standard - AASM … but the FDA might state that there are differences in patient pop etc… As such, FDA might require a small scale US based trial. TBC

Safe and effective language

Relevant to regulatory requirements

Safety – false results in resapp’s case (safety and efficacy closely linked for us)

Screening tool in China?

Sanofi agreement is limited to direct to consumer (scope deliberately limited by Tony)

Sanofi have global presence (including china)

Re telehealth etc – ResApp is actively talking to potential Chinese partners… china is a difficult market to enter though (will continue to have a number of discussions, until likely entering a strategic partnership)

Has ResApp been approached by any of Sanofi competitors approaching even before or after the agreement was put in place

Tony – “Cant comment”

Working hard with European providers to lock in deals / MOU within next month

Competitors?

Haven’t seen too many players in space

There are a few that Tony is aware of… however they are operating in slightly separate space

Most looking at specialist hardware devices, monitoring devices …”we have carved a very strong niche”… big players so far have focussed on cardiovascular disease and diabetes (the easier wins), inevitably they will turn there focus to respiratory disease, but we have a strong competitive advantage (both tech and clinical data)

Drowzle (re sleep apnoea)

Tony pointed out there submission was not a de novo application but rather 510(k)

Their approval could potentially make it easier for us re reg approval

In their 510(K) approval – there approval related to not only algos for sound + also required the accompaniment of a standard questionaries (the imposition of a questionnaire was a requirement of their approval)

Our results have been based off not including an accompanying questionnaire

Tony believes we have a competitive advantage re our tech, as well of business wise we are taking different approach. Their approach seems to focus on health and wellness. Our focus is clinical and medical – medical device company

Our strategy = get clinical buy in before release product to the world

ResApp Staff mix:

All staff currently based in Brisbane

Small team doing algo work

Small team re app development

Clinical team and reg –

3 people doing BD and sales – Tony, BD development manager, emerging markets leader

Currently hiring – shortlist for head of sales & marketing in UK (ee growth will come on sales side going forward).. but don’t expect large scale ee base given that the focus in Europe and other markets atm is B2B (e.g. 5 NHS hospitals in London)

Note: Small = less than 5 people for each team

Total headcount today = 16

Feedback on FDA

Experian – Reg person spoke to Experien 2 days ago.

“there is no delay”

Not in the middle but not at the end just yet

Conservative estimate

India and china market possibilities

China

Reg process is “extremely complex, more complex than FDA”.. company has a roadmap in place. Requires a local study in China. FDA doesn’t remove requirement to run local study in China. All Class 2 devices in China must have a local study

As such, ResApp looking for strategic partners

India

Slightly different approach re reg

Ramsay health care partnership – would we look to leverage their network in other countries e.g. France?

Have already been working with them in in Perth. Having a number of discussions at different levels. A lot of influence comes from the clinicians themselves (i.e. whilst you might have hospital management on board it is equally or more important to get clinicians to buy in)

Over last 12mths key focus has been getting clinicians on board through research journals and presentations

Presentations and papers to date – have been “exceptional well received”

Costing of devices

$5-$10 per use still holds – this price point has held up well with telehealth ($50-$60 for telehealth atm)… and reasonably well for hospitals

Sleep ap – still looking at strategy – e.g. partnerships, to consumer, to sleep ap labs

Goal = allow broad use at cheap priceNote – test in their own homes for sleep apnoea – whether class 1 or class 2 unclear atm. EU regs changing, which is pushing a lot of previous class 1 classifications into class 2… class 2 requires formal review of the company’s technical file

Wearable devices

Multiple avenues

Near term op – chronic asthma or COPD

Longer term – gives ability to collect data… 24/7 monitoring of healthy people

TGA adults approval

Lack of TGA adults approval not an issue in regards to commercialisation efforts

Unfortunately little snag with adults… why? Due to change of company address. Had to wait for BSI to update information which meant TGA paused application\

Expect to be resolved in days or maybe weeks

IP protection and status of tech

Generation 1 now

Generation 2 – R&D taem currently working on a number of things. Tony is excited about the improvements… which makes some “pretty material improvements”!

Primary IP of computer source code + clinical data… a lot of security processes in place to protect these (i.e. ResApp does not provide source code to any partner atm and don’t expect to going forward…

R&D

Expect $1.8m for 2019 and to receive before end of the quarter

Similar for 2020

US adult study

o At best would commence this US winter. Adults expect quicker recruitment + enrolment also less seasonal in nature vs kid

Expand

Cheers! Thanks for sharing that.
RAP Price at posting: 28.5¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

RAD

Radiopharm extends radioimmunotherapy trial to 5 more cancer types

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

JLL

Jindalee Lithium chasing key role in US battery chain after McDermitt prefeasibility study

PAM

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

First 19 Last

Add RAP (ASX) to my watchlist